Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1991

1.

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MÁ, Cortés J, Rojo F, Martín M, Palacios-Calvo J.

Clin Transl Oncol. 2018 Jun 18. doi: 10.1007/s12094-018-1909-1. [Epub ahead of print]

PMID:
29916189
2.

Enhanced prefrontal functional-structural networks to support postural control deficits after traumatic brain injury in a pediatric population.

Diez I, Drijkoningen D, Stramaglia S, Bonifazi P, Marinazzo D, Gooijers J, Swinnen SP, Cortes JM.

Netw Neurosci. 2017 Jun 1;1(2):116-142. doi: 10.1162/NETN_a_00007. eCollection 2017 Spring.

PMID:
29911675
3.

Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.

López JI, Pulido R, Cortés JM, Angulo JC, Lawrie CH.

Pathol Res Pract. 2018 Jun 12. pii: S0344-0338(18)30539-9. doi: 10.1016/j.prp.2018.06.003. [Epub ahead of print]

PMID:
29910061
4.

Introduction to a review series on Adolescent and Young Adult Malignant Hematology.

Cortes J.

Blood. 2018 Jun 12. pii: blood-2018-05-846105. doi: 10.1182/blood-2018-05-846105. [Epub ahead of print] No abstract available.

PMID:
29895663
5.

Conformational changes in antibody Fab fragments upon binding and their consequences on the performance of docking algorithms.

Barozet A, Bianciotto M, Siméon T, Minoux H, Cortés J.

Immunol Lett. 2018 Jun 6;200:5-15. doi: 10.1016/j.imlet.2018.06.002. [Epub ahead of print]

PMID:
29885326
6.

Response kinetics and factors predicting survival in core-binding factor leukemia.

Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduike R, Kantarjian H, Borthakur G.

Leukemia. 2018 Jun 8. doi: 10.1038/s41375-018-0158-1. [Epub ahead of print] No abstract available.

PMID:
29884905
7.

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.

Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, Muñoz-Couselo E, Nuciforo P, Cortés J, Nötzel C, Kumarakulasinghe NB, Richard JLC, Bin Adam Isa ZF, Pang B, Guzman M, Siqin Z, Yang H, Tam WL, Serra V, Eichhorn PJA.

J Exp Med. 2018 Jun 7. pii: jem.20171960. doi: 10.1084/jem.20171960. [Epub ahead of print]

PMID:
29880484
8.

nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.

Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators.

Ann Oncol. 2018 Jun 6. doi: 10.1093/annonc/mdy201. [Epub ahead of print]

PMID:
29878040
9.

Phase 2b study of two dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Jun 6. pii: blood-2018-01-821629. doi: 10.1182/blood-2018-01-821629. [Epub ahead of print]

PMID:
29875101
10.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M.

Lancet Oncol. 2018 May 30. pii: S1470-2045(18)30240-7. doi: 10.1016/S1470-2045(18)30240-7. [Epub ahead of print]

PMID:
29859851
11.

Reply to K.S. Shohdy et al.

Traina TA, Cortes J.

J Clin Oncol. 2018 May 30:JCO2018788349. doi: 10.1200/JCO.2018.78.8349. [Epub ahead of print] No abstract available.

PMID:
29847296
12.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 May 24. pii: haematol.2018.191361. doi: 10.3324/haematol.2018.191361. [Epub ahead of print] No abstract available.

13.

Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.

Gomez-Lumbreras A, Cortes J, Giner-Soriano M, Quijada-Manuitt MA, Morros R.

J Cardiovasc Pharmacol Ther. 2018 Jan 1:1074248418778544. doi: 10.1177/1074248418778544. [Epub ahead of print]

PMID:
29792125
14.

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2018 May 18. doi: 10.1093/jnci/djy076. [Epub ahead of print]

PMID:
29788230
15.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ.

Haematologica. 2018 May 17. pii: haematol.2017.171249. doi: 10.3324/haematol.2017.171249. [Epub ahead of print]

16.

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E.

Br J Cancer. 2018 May 16. doi: 10.1038/s41416-018-0082-1. [Epub ahead of print]

PMID:
29765150
17.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS.

Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041. eCollection 2018 Apr 17.

18.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158. [Epub ahead of print]

PMID:
29741984
19.

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2018 Jul 1;124(13):2740-2747. doi: 10.1002/cncr.31357. Epub 2018 May 3.

PMID:
29723397
20.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2018 Apr 30. doi: 10.1093/annonc/mdx804. [Epub ahead of print] No abstract available.

PMID:
29718117
21.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.

PMID:
29706375
22.

Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.

Cortes J, Pérez-García J, Whiting S, Wan Y, Solem C, Tai MH, Margunato-Debay S, Ko A, Fandi A, Botteman M.

Clin Breast Cancer. 2018 Mar 30. pii: S1526-8209(17)30778-4. doi: 10.1016/j.clbc.2018.03.014. [Epub ahead of print]

23.

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K.

J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.

PMID:
29702001
24.

Excavating sponges from the Pacific of Central America, descriptions and a faunistic record.

Pacheco C, Carballo JL, CortÉs J, Segovia J, Trejo A.

Zootaxa. 2018 Jan 15;4370(5):451-491. doi: 10.11646/zootaxa.4370.5.1.

PMID:
29689819
25.

The new world of biosimilars in oncology: Translation of data to the clinic.

Rugo HS, Cortes J.

Eur J Cancer. 2018 Jun;96:125-127. doi: 10.1016/j.ejca.2018.03.005. Epub 2018 Apr 18. No abstract available.

PMID:
29680363
26.

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Apr 19. doi: 10.1038/s41556-018-0052-0. [Epub ahead of print]

PMID:
29674681
27.

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G.

Cancer. 2018 Jul 1;124(13):2758-2765. doi: 10.1002/cncr.31398. Epub 2018 Apr 16.

PMID:
29660836
28.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.

Cancer. 2018 Jun 15;124(12):2534-2540. doi: 10.1002/cncr.31370. Epub 2018 Apr 12.

PMID:
29645075
29.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.

Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.

30.

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.

Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA.

Clin Cancer Res. 2018 Apr 4. doi: 10.1158/1078-0432.CCR-17-3059. [Epub ahead of print]

PMID:
29618616
31.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.

BMC Cancer. 2018 Apr 2;18(1):359. doi: 10.1186/s12885-018-4273-1.

32.

[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R.

Rev Esp Patol. 2018 Apr - Jun;51(2):97-109. doi: 10.1016/j.patol.2017.12.002. Epub 2018 Mar 14. Spanish.

PMID:
29602380
33.

Consensus clustering approach to group brain connectivity matrices.

Rasero J, Pellicoro M, Angelini L, Cortes JM, Marinazzo D, Stramaglia S.

Netw Neurosci. 2017 Oct 1;1(3):242-253. doi: 10.1162/NETN_a_00017.

34.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086. [Epub ahead of print]

PMID:
29567798
35.

Burden of Fungal Infections in Colombia.

Alvarez-Moreno CA, Cortes JA, Denning DW.

J Fungi (Basel). 2018 Mar 21;4(2). pii: E41. doi: 10.3390/jof4020041.

36.

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z.

Ann Hematol. 2018 Jul;97(7):1183-1191. doi: 10.1007/s00277-018-3289-6. Epub 2018 Mar 20.

PMID:
29557496
37.

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J.

Lancet Haematol. 2018 Apr;5(4):e136-e146. doi: 10.1016/S2352-3026(18)30021-8. Epub 2018 Mar 14.

PMID:
29550383
38.

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S.

J Hematol Oncol. 2018 Mar 15;11(1):42. doi: 10.1186/s13045-018-0585-5.

39.

Impact of Medication Adherence on Mortality and Cardiovascular Morbidity: Protocol for a Population-Based Cohort Study.

Giner-Soriano M, Sotorra Figuerola G, Cortés J, Pera Pujadas H, Garcia-Sangenis A, Morros R.

JMIR Res Protoc. 2018 Mar 9;7(3):e73. doi: 10.2196/resprot.8121.

40.

Teaching Cell Biology to Dental Students with a Project-Based Learning Approach.

Costa-Silva D, Côrtes JA, Bachinski RF, Spiegel CN, Alves GG.

J Dent Educ. 2018 Mar;82(3):322-331. doi: 10.21815/JDE.018.032.

PMID:
29496812
41.

Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.

Cortes J, Perez-Garcia J, Levy C, Gómez Pardo P, Bourgeois H, Spazzapan S, Martínez-Jañez N, Chao TC, Espié M, Nabholtz JM, Gonzàlez Farré X, Beliakouski V, Román García J, Holgado E, Campone M.

Ann Oncol. 2018 Apr 1;29(4):881-887. doi: 10.1093/annonc/mdy051.

PMID:
29481630
42.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.

Gonzalez-Cao M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, Molina-Vila MÁ, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Spanish Melanoma Group.

Melanoma Res. 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432.

PMID:
29481492
43.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29466766
44.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.

Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H.

Int J Hematol. 2018 Jun;107(6):689-695. doi: 10.1007/s12185-018-2422-6. Epub 2018 Feb 20.

PMID:
29464484
45.

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.

Clin Cancer Res. 2018 May 15;24(10):2417-2429. doi: 10.1158/1078-0432.CCR-17-1556. Epub 2018 Feb 20.

PMID:
29463558
46.

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE.

Clin Cancer Res. 2018 May 15;24(10):2294-2303. doi: 10.1158/1078-0432.CCR-17-2824. Epub 2018 Feb 20.

PMID:
29463550
47.

Habitat characteristics provide insights of carbon storage in seagrass meadows.

Mazarrasa I, Samper-Villarreal J, Serrano O, Lavery PS, Lovelock CE, Marbà N, Duarte CM, Cortés J.

Mar Pollut Bull. 2018 Feb 16. pii: S0025-326X(18)30070-5. doi: 10.1016/j.marpolbul.2018.01.059. [Epub ahead of print]

PMID:
29459167
48.

Segmenting Proteins into Tripeptides to Enhance Conformational Sampling with Monte Carlo Methods.

Denarie L, Al-Bluwi I, Vaisset M, Siméon T, Cortés J.

Molecules. 2018 Feb 9;23(2). pii: E373. doi: 10.3390/molecules23020373.

49.

RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.

Cortes JR, Ambesi-Impiombato A, Couronné L, Quinn SA, Kim CS, da Silva Almeida AC, West Z, Belver L, Martin MS, Scourzic L, Bhagat G, Bernard OA, Ferrando AA, Palomero T.

Cancer Cell. 2018 Feb 12;33(2):259-273.e7. doi: 10.1016/j.ccell.2018.01.001. Epub 2018 Feb 2.

PMID:
29398449
50.

Evidence for a subcortical origin of mirror movements after stroke: a longitudinal study.

Ejaz N, Xu J, Branscheidt M, Hertler B, Schambra H, Widmer M, Faria AV, Harran MD, Cortes JC, Kim N, Celnik PA, Kitago T, Luft AR, Krakauer JW, Diedrichsen J.

Brain. 2018 Jan 31. doi: 10.1093/brain/awx384. [Epub ahead of print]

PMID:
29394326

Supplemental Content

Loading ...
Support Center